Straits Times Index
3,137.54 +25.89 (+0.83%) S&P 500
3,911.74 +116.01 (+3.06%) Dow
31,500.68 +823.28 (+2.68%) Nasdaq
11,607.62 +375.42 (+3.34%) BTC-USD
21,427.51 +12.42 (+0.06%) CMC Crypto 200
467.40 +13.50 (+2.98%)
BioCryst Pharmaceuticals, Inc. (BCRX)
After hours:
| Previous close | 10.17 |
| Open | 10.25 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 1800 |
| Day's range | 10.20 - 10.91 |
| 52-week range | 7.61 - 19.99 |
| Volume | |
| Avg. volume | 4,927,146 |
| Market cap | 1.997B |
| Beta (5Y monthly) | 2.51 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.07 |
| Earnings date | 03 Aug 2022 - 08 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.45 |
- Zacks
Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength?
BioCryst (BCRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Motley Fool
Why BioCryst Pharmaceuticals Topped the Market Today
BioCryst Pharmaceuticals (NASDAQ: BCRX) stock defied the market's gravity on Wednesday by rising incrementally. Although it was a challenging day for stocks in general, with the S&P 500 index sinking by over 1%, BioCryst landed in the black thanks to some encouraging regulatory news. Before market open, BioCryst announced that the Food and Drug Administration (FDA) has granted its BCX9250 investigational drug fast-track designation.
- Motley Fool
Why BioCryst Stock Lost Nearly 4% of Its Value Today
The biotech whiffs on both revenue and profitability for its first quarter, and indicates more losses are in store.
